Market Newsdesk

HOUSTON, TX, Jan. 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — StemGen (OTC: SGNI), a leading broad automotive engineering and esports technology company, today announced the launch of its newly redesigned website – https://stemgeninc.com, as part of a brand refresh campaign initiated by the company late in 2020. The new website is well positioned as a leading source for insights, solutions, and interactive features for the motorsports technology industry.  The new site has been optimized to ensure visitors are provided a great user experience across all digital devices, including desktop, tablet and mobile.

Another key part of the branding initiative was a complete logo redesign.  The new design speaks to the future of the company by combining real-world racing data technologies, STEM (Science, Technology, Engineering, and Math) education, and interactive driving simulation systems.  Overall, the branding campaign is intended to mark a new era in the history of StemGen. 

“We have proven track record of building and scaling brands with exceptional success,” says Simon Dawson, president and chief executive officer of StemGen. “As part of our renewed vision and our expanding our lines of business, now was a great time to ensure our brand identity and have our website reflect where we are going.  For us this is more than just a new logo. We wanted this to represent our new direction. We’re excited to have a new look that better reflects the growth and evolution of our company over the last two years.”

One key feature of the new website includes an improved investor information section for current and prospective shareholders to gain important insights into our industry and the subsidiaries of StemGen.  The roadmap for the website is to expand investor communication and interactivity as we continue to evolve in the coming weeks. 

For more information about StemGen Inc., please visit https://stemgeninc.com/

ABOUT STEMGEN, INC.

StemGen, Inc. (OTC: SGNI) is a broad automotive engineering and esports technology company focused on the digital transformation of motorsports, gaming, and education. The Company generates revenues through the licensing of in-house developed hydrogen-fueled automotive technologies, audience and education monetization programs delivered through virtual motor sports events platform, and Direct to Consumer (DTC) sale of purpose-built racing simulators and esports retail products. StemGen manages racing and gaming operations on a global basis from the corporate headquarters located in Houston, TX. Visit www.stemgeninc.com for more information. 

Notice Regarding Forward-Looking Statements – Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

CONTACT:   

Barbara J. Burns

Burns | Group PR

[email protected]

+1 770-329-7134

ROSELAND, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today raised revenue guidance to over $2 million for the fourth quarter of 2020, a 67% sequential increase over $1.2 million reported for the third quarter of 2020.

Arjan Haverhals, President of Milestone Scientific and CEO of Wand Dental Inc., stated, “I am pleased to report we are increasing our revenue guidance to over $2 million for the fourth quarter of 2020, which compares favorably to the $1.2 million we reported for the third quarter of 2020, and our prior guidance of $1.7 million, which we had previously forecast for the fourth quarter of 2020. We attribute this strong performance to the improvement in our dental business, which has continued to recover as dental offices reopen across the country and around the world. Notably, this guidance does not include recent sales to our Chinese distributor of approximately $450,000, which we will only record as revenue when the inventory is resold by our distributor. In addition to our revenue growth, we are seeing improvement in our cash flow. Given our strong cash position at the end of the third quarter, we are well funded to support our growth initiatives within the medical division and have no plans to raise capital for the foreseeable future.”

“At the same time, I am pleased to report we are gaining traction with our CompuFlo® Epidural System. Specifically, we recently announced we have begun selling CompuFlo® disposables to the University of Texas Medical Branch at Galveston (UTMB), an institution of the University of Texas System and agency of the State of Texas. We anticipate adding additional hospitals during the first quarter of 2021 and remain steadfast in our goal of establishing the CompuFlo Epidural System as the new standard of care in epidural anesthesia.”

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020

Irvine, CA, Jan. 06, 2021 (GLOBE NEWSWIRE) — FDCTech, Inc. (“FDC” or the “Company,” OTCQB: FDCT), a fintech company with a full suite of FX and Crypto technology and business solutions, today announced that Kammas Trading, which has managed risk for brokers for over 15 years trading aggregate monthly flows above $50 Billion has partnered with FDC to provide a collective offering to include the full suite of technology and dealing desk solutions to forex brokers.

This mutual partnership allows FDC to market and promote its fully customizable proprietary trading platform technology to Kammas‘ network of institutional clients. Experienced FX dealers make-up Kammas team with decades of experience on major FX bank desks, including managing dealing and trading risks at Bank of America, Merrill Lynch, Goldman Sachs, BNP, Bank Austria, West LB, Bank of New York, and Prudential.

FDC’s technology solutions cover the whole spectrum of needs of any FX or Crypto Broker. Firstly, FDC’s Condor FX Pro Trading Platform can be deployed as an off-the-shelf trading platform to enable FX and Crypto brokers to become fully operational within days. Secondly, these brokers can fully customize the back-end configurations to the front-end user interface to other structural adjustments, thus providing a unique trading experience to their clients and eliminate several third-party technology vendors’ requirements.

Kammas
‘ CEO and Founder, Carl Elsammak, an FX dealing desk and risk manager since 1990, said, “We are excited to actively co-market our respective capabilities to the various forex market participants, which ranges from professional traders to forex brokers to banks. FDC has software capabilities to build state-of-the-art complex trading software most cost-effectively.”

FDC’s Chief Executive Officer, Mitchell M. Eaglstein, stated, “This co-marketing agreement aligns with our strategy of bundling our technology capabilities with Kammas institutional risk management services. This partnership will have a meaningful market impact as we are providing our clients with a one-stop-shop for all the trading technology solutions and dealing desk services.”

About Kammas Trading


Kammas Trading
is a U.S. based company, providing the dealing desk and prime brokerage consulting services to forex brokers since 2002. Kammas currently manages risk for brokers with aggregate monthly flows above $50 Billion and has earned well over $150 million for its clients above STP.

FDCTech, Inc.

FDCTech, Inc. (“FDC”), formerly known as Forex Development Corporation, is a US-based, fully integrated financial technology company. FDC delivers trading technology solutions to forex market participants looking to access the retail and institutional spot forex markets.

Recent Promotional and Trading Activities at Request of OTC Markets

The Company became aware of certain promotional activities concerning its common stock on January 4, 2020, through a notification from Issuer Services at OTC Markets Group (OTC Markets); for detail, please see our press release regarding recent promotional and trading activities.

Press Release Disclaimer

Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets, and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. The Company does not make any representation or warranty, express or implied, regarding the accuracy, completeness, or updated status of such forward-looking statements or information provided by the third-party. Therefore, in no case whatsoever will Company and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or any related damages.

Contact Media Relations

FDCTech, Inc.
[email protected]
www.fdctech.com
+1 877-445-6047
200 Spectrum Drive, Suite 300,
Irvine, CA, 92618

WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) — Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 32,630,983 of its shares of common stock at a purchase price of $1.10 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about January 8, 2021, subject to the satisfaction of customary closing conditions.

JonesTrading Institutional Services LLC (“JonesTrading”) is acting as the placement agent for the offering.

The gross proceeds to Aileron from the offering are expected to be $35.9 million, before deducting the placement agent’s fees and other offering expenses payable by Aileron.

Aileron intends to use the net proceeds from the public offering, together with its existing cash, cash equivalents and short-term investments, to fund clinical development of ALRN-6924 as a chemoprotective agent and for working capital and other general corporate purposes.

The shares are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-226650) that was filed with the United States Securities and Exchange Commission (“SEC”) on August 7, 2018, and declared effective by the SEC on July 15, 2019. A prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. The offering is being made only by means of a prospectus and related prospectus supplement. When available, electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained from JonesTrading Institutional Services LLC by calling (212) 907-5332, or by e-mailing [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Aileron Therapeutics

Aileron is clinical-stage biopharmaceutical company that is focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. ALRN-6924, the company’s first-in-class MDM2/MDMX dual inhibitor activating p53, is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which the company exclusively focuses on treating patients with p53-mutated cancers.  

Forward-Looking Statements

Statements in this press release about Aileron’s future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, including statements about the expected closing of the offering and anticipated proceeds from the offering, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Aileron’s strategy, financing, and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the conditions to the closing of the offering will be satisfied; and other factors discussed in the “Risk Factors” section of Aileron’s quarterly report on Form 10-Q for the period ended September 30, 2020, filed on November 12, 2020, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Investor Contacts:                                        
Richard Wanstall, SVP Chief Financial Officer                
Aileron Therapeutics                                        
617-995-0900                                               
[email protected]

Hans C. Vitzthum
LifeSci Advisors, LLC.
617-430-7578
[email protected]

Media Contact:
Liz Melone
617-256-6622
[email protected]

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 6.0 million shares of common stock at a price of $2.24 per share for gross proceeds of approximately $13.4 million in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules.

The estimated net proceeds to PAVmed from the Offering are expected to be approximately $12.4 million after deducting the placement agent’s fees and other estimated offering expenses. The Offering is expected to close on or about January 8, 2021 subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as the sole placement agent in connection with the Offering.

The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-248709) declared effective by the Securities and Exchange Commission on September 17, 2020. A prospectus supplement relating to the Offering is being filed with the Securities and Exchange Commission. Copies of the prospectus supplement relating to the offering, together with the accompanying base prospectus included in the registration statement, may be obtained from the Securities and Exchange Commission at www.sec.gov, or from the Company at One Grand Central Place, Suite 4600, New York, New York 10165, Telephone (212) 949-4319. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About PAVmed

PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical device company employing a unique business model designed to advance innovative products to commercialization rapidly and with less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation while seeking to further expand its pipeline through relationships with its network of clinician innovators at leading academic centers. PAVmed’s diversified product pipeline addresses unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its four operating divisions include GI Health (EsoGuard^® Esophageal DNA Test, EsoCheck^® Esophageal Cell Collection Device, and EsoCure^™ Esophageal Ablation Device with Caldus^™ Technology), Minimally Invasive Interventions (CarpX^® Minimally Invasive Device for Carpal Tunnel Syndrome), Infusion Therapy (PortIO^™ Implantable Intraosseus Vascular Access Device and NextFlo^™ Highly Accurate Infusion Platform Technology), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and Instagram.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, PAVmed’s ability to complete the offering; volatility in the price of PAVmed’s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s preclinical studies; whether and when PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company’s financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s future operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Contacts:

Investors

Mike Havrilla
Director of Investor Relations
(814) 241-4138
[email protected]

Media

Shaun O’Neil
Chief Commercial Officer
(518) 812-3087
[email protected]

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) — Veritas Advisory Group, a SOCOTEC Company (Veritas) announced today that Helmes & Co, LLC have joined the firm. Located in Boston, MA, Helmes & Co is a project advisory firm focused on the deployment, operation, and analysis of capital projects worldwide – from residential, commercial, process, generating facilities to major civil infrastructure. Phillip Helmes will continue leading his team in his new role as Regional Director, joining the nationally renowned team of consultants advising clients across a variety of end markets including rail, airport, highway, bridge, tunnel, powerplant, oil and gas, chemical, wastewater treatment, as well as residential and commercial building projects.

“The entire team at Helmes & Co is pleased to be joining Veritas, a SOCOTEC Company, a leading group in Testing Inspection and Certification in the Building and Infrastructure sectors. The partnership will enhance our capabilities in providing clients and law firms strategic insights into construction and engineering project management. A special thanks to our many long-term clients for their trust in our capabilities which has allowed us to build a truly respected firm. With the support and backing of a top-tier partner, we are now in a position to build on decades of expertise and efficiently deliver a more comprehensive offering of project management and technical analysis for our clients,” said Phillip Helmes.

Rodney Sowards, President of Veritas, continues, saying, “Veritas is excited to expand our services into Boston, and into the northeast, with the addition of Helmes and Co. Phil Helmes and his team of professionals will enhance our Project Advisory and Dispute Resolution practice areas and will strengthen Veritas’ position as a national leader in construction advisory, dispute, and forensic services.”

“Despite the challenges we all experienced throughout 2020, we remain focused on our plan to expand project advisory services throughout North America,” said Marc Weissbach, Chief Executive Officer of Vidaris. “Phil Helmes and his team bring decades of expertise in advising clients throughout complex building projects. Helmes’ service offering is complimentary to the niche services provided by Vidaris and our affiliates.”

Including Vidaris’ network of affiliate companies – Veritas, LPI, CBI Consulting, C2G International, Synergen Consulting International, David Pattillo & Associates, and Construction Project Analytics Group – all of which are part of the SOCOTEC Group – the Company has over 350 highly regarded professionals in 21 offices providing solutions within six closely-integrated services: building envelope, energy efficiency and sustainability, dispute resolution, project advisory, code compliance and specialty engineering.

Davis Malm acted as legal counsel to Helmes & Co in connection with the transaction. Honigman, LLP provided legal counsel to the SOCOTEC entities.

About Veritas Advisory Group

Veritas Advisory Group, Inc. is a business consulting and forensic advisory firm that helps clients solve the financial, economic, and dispute-related problems faced in today’s diverse business environment. Its team of engineers, CPAs, MBAs, financial analysts, and building industry professionals consult with a wide array of public entities, governmental agencies, private companies, sureties, and the law firms who serve them. Through numerous engagements, Veritas has provided a wide variety of services including claims evaluation and resolution, financial damage assessment, insured loss analysis, construction claims preparation and review, project management advisory services, fraud investigations, class action administration and distribution, expert witness testimony, and litigation support.

See www.veritasag.com for more information.

About Vidaris

Vidaris is a leading TIC (testing, inspection and certification) consultancy focused on assurance services, building design, efficiency and dispute resolution in the construction, real estate, infrastructure and industrial fields, serving as an independent third‐party advisor for leading developers, property owners, industrial operators, utilities, architects and engineers. The Company’s multidisciplinary, highly technical and integrated service offering includes three major segments: (i) Architectural Consulting, Testing, Inspection and Certification (« ATIC »); (ii) Dispute Resolution (« DR »); and (iii) Engineering Consulting, Testing, Inspection and Certification (« ETIC ») on both existing and new assets.

See www.vidaris.com for more information.

About The SOCOTEC Group

The SOCOTEC Group, headed by Hervé Montjotin, has built its reputation over more than 60 years as a trusted partner assisting companies in the areas of quality, health and safety, and the environment.

SOCOTEC’s mission is to ensure the integrity and performance of assets and people’s safety. Through its inspection and measurement, assistance and consultancy, and training and certification services, SOCOTEC helps to optimize the performance of companies in every sector by managing the risks inherent in their activities. Drawing on its expertise and positioning itself as a long-term partner, SOCOTEC supports its clients throughout their project’s lifecycle.

As a leader in building inspection and a major player in TIC for the construction and infrastructure sectors, the SOCOTEC Group has 200,000 clients with operations in 23 countries, 9,000 employees and over 250 forms of external recognition.

See www.socotec.com for more information.

Michelle Maxwell
Vidaris, Inc.
+1 212 689 5389 x168
[email protected]